RNA-sequencing of acute promyelocytic leukemia primary blasts reveals novel molecular biomarkers of early death events.
Johann-Christoph JannAlexander StreuerAnna HechtFlorian NolteVerena NowakJustine DannerJulia ObländerIris PalmeEva LengfelderUwe PlatzbeckerWolf-Karsten HofmannJohanna FlachDaniel NowakPublished in: Leukemia & lymphoma (2020)
Although acute promyelocytic leukemia (APL) has evolved to the AML entity with the best prognosis, typical 'early death' (ED) events still account for mortality rates of ∼20% in population-based studies. To investigate this poorly understood issue we performed whole transcriptome analysis of n = 7 APL ED cases compared to n = 7 APL cases with long term remission. We discovered the proteins S100A8/S100A9 and EFEMP1 as the most differentially expressed factors. In an independent cohort of n = 58 APL patients EFEMP1 over-expression was associated with a worse overall survival. Furthermore, a subgroup analysis of ED caused by hemorrhagic complications revealed an association of metallothioneins (MT1G/MT1E) with higher bleeding rates, ED events and negative prognostic effects on overall survival. Finally, we identified a novel TPM4-KLF2 fusion transcripts in 44/64 APL samples. In summary, we report a comprehensive transcriptomic analysis and novel potential biomarkers of ED biology, which highlight novel pathways in ED events in APL.
Keyphrases
- emergency department
- acute myeloid leukemia
- single cell
- liver failure
- end stage renal disease
- bone marrow
- respiratory failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- poor prognosis
- risk factors
- prognostic factors
- drug induced
- gene expression
- rna seq
- cardiovascular disease
- randomized controlled trial
- genome wide
- atrial fibrillation
- transcription factor
- free survival
- extracorporeal membrane oxygenation
- intensive care unit
- rheumatoid arthritis
- patient reported outcomes
- open label
- long non coding rna
- ulcerative colitis
- placebo controlled
- double blind